Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Long-Term Survival Analysis of the North American Intergroup Study C9011 Comparing Fludarabine (F) and Chlorambucil (C) in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL).

Kanti R. Rai, MD, Bercedis L. Peterson, Ph.D, Frederick R. Appelbaum, MD, Martin S. Tallman, MD, Andrew Belch, MD, Vicki A. Morrison, MD, Richard A. Larson, MD

Blood (2009) 114 (22): 536.

https://doi.org/10.1182/blood.V114.22.536.536

Published: 2009

Journal Articles

Consolidation Therapy with Subcutaneous (SC) Alemtuzumab Results in Severe Infectious Toxicity in Previously Untreated CLL Patients Who Achieve a Complete Response (CR) after Fludarabine and Rituximab (FR) Induction Therapy: Interim Safety Analysis of the CALGB Study 10101.

Thomas S. Lin, MD, PhD, Kathleen A. Donohue, MA, Margaret S. Lucas, BS, PA, John C. Byrd, MD, Elizabeth M. Bengtson, MD, Bercedis L. Peterson, PhD, Richard A. Larson, MD

Blood (2007) 110 (11): 755.

https://doi.org/10.1182/blood.V110.11.755.755

Published: 2007

Journal Articles

Alemtuzumab Increases Serious Infections in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) Receiving Fludarabine-Based Therapy: A Comparative Analysis of 3 Cancer and Leukemia Group B Studies (CALGB 9011, 9712, 19901).

Vicki A. Morrison, MD, Bercedis L. Peterson, PhD, Kanti R. Rai, MD, John C. Byrd, MD, Richard A. Larson, MD

Blood (2007) 110 (11): 756.

https://doi.org/10.1182/blood.V110.11.756.756

Published: 2007

Journal Articles

Bortezomib and Pegylated Liposomal Doxorubicin as Induction Therapy for Adult Patients with Symptomatic Multiple Myeloma: Cancer and Leukemia Group B Study 10301.

Robert Z. Orlowski, MD, PhD, Bercedis L. Peterson, PhD, Ben Sanford, Asher A. Chanan-Khan, MD, Lee M. Zehngebot, MD, Peter R. Watson, MD, Michael A. Caligiuri, MD, Richard A. Larson, MD, the Cancer Leukemia Group B

Blood (2006) 108 (11): 797.

https://doi.org/10.1182/blood.V108.11.797.797

Published: 2006

Journal Articles

Multivariate Analysis of Patient and Graft Specific Factors among 330 Recipients of Unrelated Cord Blood Transplant (UCBT) To Predict Risk of Death from Opportunistic Infections in the First 6 Months after UCBT.

Paul Szabolcs, MD, Bercedis L. Peterson, PhD, Donna Niedzwiecki, PhD, Nelson Chao, MD, Joanne Kurtzberg, MD

Blood (2006) 108 (11): 2860.

https://doi.org/10.1182/blood.V108.11.2860.2860

Published: 2006

Journal Articles

Response Rates in Patients with Acute Myeloid Leukemia (AML), Treated with Azacitidine, Using WHO and International Working Group (IWG) Criteria for Myelodysplastic Syndrome (MDS).

Lewis R. Silverman, MD, David R. McKenzie, MS, Bercedis L. Peterson, PhD, Richard M. Stone, MD, Bayard L. Powell, MD, Christy Mayo, MS, Jay T. Backstrom, MD, MPH, Richard A. Larson, MD, The Cancer Leukemia Group B (CALGB)

Blood (2005) 106 (11): 1848.

https://doi.org/10.1182/blood.V106.11.1848.1848

Published: 2005

Journal Articles

Analysis of Survival, AML Transformation, and Transfusion Independence in Patients with High-Risk Myelodysplastic Syndromes (MDS) Receiving Azacitidine Determined Using a Prognostic Model.

Lewis R. Silverman, MD, David R. McKenzie, MS, Bercedis L. Peterson, PhD, Erin P. Demakos, RN, CCRC, James F. Holland, MD, Richard R. Larson, MD, The Cancer Leukemia Group B (CALGB).

Blood (2005) 106 (11): 2523.

https://doi.org/10.1182/blood.V106.11.2523.2523

Published: 2005

Journal Articles

Azacitidine Prolongs Survival and Time to AML Transformation in High-Risk Myelodysplastic Syndrome (MDS) Patients ≥ 65 Years of Age.

Lewis R. Silverman, MD, David R. McKenzie, MS, Bercedis L. Peterson, PhD, Erin P. Demakos, RN, CCRC, Neil T. Malone, MA, James F. Holland, MD, Richard A. Larson, MD, The Cancer Leukemia Group B (CALGB).

Blood (2005) 106 (11): 2524.

https://doi.org/10.1182/blood.V106.11.2524.2524

Published: 2005

Journal Articles

Rates of Infection and Bleeding Are Not Increased in Patients with Myelodysplastic Syndromes (MDS) Treated with Azacitidine Compared with Supportive Care.

Lewis R. Silverman, MD, David R. McKenzie, MS, Bercedis L. Peterson, PhD, Rosalie Odchimar-Reissig, RN, MSN, CCRC, Randy Hinkle, RPh, Jay T. Backstrom, MD, Richard A. Larson, MD, The Cancer Leukemia Group B (CALGB).

Blood (2005) 106 (11): 2525.

https://doi.org/10.1182/blood.V106.11.2525.2525

Published: 2005

Journal Articles

Response Rates Using International Working Group (IWG) Criteria in Patients with Myelodysplastic Syndromes (MDS) Treated with Azacitidine.

Lewis R. Silverman, MD, David R. McKenzie, MS, Bercedis L. Peterson, PhD, Carlos M. De Castro, MD, John Ellerton, MD, Kathryn N. Knapp, MS, C.L. Beach, PharmD, Richard A. Larson, MD, The Cancer Leukemia Group B (CALGB).

Blood (2005) 106 (11): 2526.

https://doi.org/10.1182/blood.V106.11.2526.2526

Published: 2005

Journal Articles

A New Validated Myelodysplastic Syndrome (MDS) Prognostic Model for Use When Cytogenetics Are Unavailable.

Lewis R. Silverman, MD, Ulrich Germing, MD, PhD, David R. McKenzie, MS, Bercedis L. Peterson, PhD, Richard A. Larson, MD, The Cancer Leukemia Group B (CALGB).

Blood (2005) 106 (11): 2527.

https://doi.org/10.1182/blood.V106.11.2527.2527

Published: 2005

Journal Articles

Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011

John C. Byrd, Kanti Rai, Bercedis L. Peterson, Frederick R. Appelbaum, Vicki A. Morrison, Jonathan E. Kolitz, Lois Shepherd, John D. Hines, Charles A. Schiffer, Richard A. Larson

Blood (2005) 105 (1): 49–53.

https://doi.org/10.1182/blood-2004-03-0796

Published: 2005

Journal Articles

Sequential Phase II Studies of Flavopiridol by 72-Hour Continuous Infusion and 1-Hour Intravenous Bolus for the Treatment of Relapsed B-Cell Chronic Lymphocytic Leukemia: Results from CALGB Study 19805.

John C. Byrd, MD, Bercedis L. Peterson, PhD, Janice L. Gabrilove, MD, Olatoyosi M. Odenike, MD, Michael R. Grever, MD, Kanti R. Rai, MD, James W. Vardiman, MD, Richard A. Larson, MD, Cancer and Leukemia Group B

Blood (2004) 104 (11): 3485.

https://doi.org/10.1182/blood.V104.11.3485.3485

Published: 2004

Journal Articles

Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)

John C. Byrd, Bercedis L. Peterson, Vicki A. Morrison, Kathleen Park, Robert Jacobson, Eva Hoke, James W. Vardiman, Kanti Rai, Charles A. Schiffer, Richard A. Larson

Blood (2003) 101 (1): 6–14.

https://doi.org/10.1182/blood-2002-04-1258

Published: 2003

NARROW

Long-Term Survival Analysis of the North American Intergroup Study C9011 Comparing Fludarabine (F) and Chlorambucil (C) in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL).

Consolidation Therapy with Subcutaneous (SC) Alemtuzumab Results in Severe Infectious Toxicity in Previously Untreated CLL Patients Who Achieve a Complete Response (CR) after Fludarabine and Rituximab (FR) Induction Therapy: Interim Safety Analysis of the CALGB Study 10101.

Alemtuzumab Increases Serious Infections in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) Receiving Fludarabine-Based Therapy: A Comparative Analysis of 3 Cancer and Leukemia Group B Studies (CALGB 9011, 9712, 19901).

Bortezomib and Pegylated Liposomal Doxorubicin as Induction Therapy for Adult Patients with Symptomatic Multiple Myeloma: Cancer and Leukemia Group B Study 10301.

Multivariate Analysis of Patient and Graft Specific Factors among 330 Recipients of Unrelated Cord Blood Transplant (UCBT) To Predict Risk of Death from Opportunistic Infections in the First 6 Months after UCBT.

Response Rates in Patients with Acute Myeloid Leukemia (AML), Treated with Azacitidine, Using WHO and International Working Group (IWG) Criteria for Myelodysplastic Syndrome (MDS).

Analysis of Survival, AML Transformation, and Transfusion Independence in Patients with High-Risk Myelodysplastic Syndromes (MDS) Receiving Azacitidine Determined Using a Prognostic Model.

Azacitidine Prolongs Survival and Time to AML Transformation in High-Risk Myelodysplastic Syndrome (MDS) Patients ≥ 65 Years of Age.

Rates of Infection and Bleeding Are Not Increased in Patients with Myelodysplastic Syndromes (MDS) Treated with Azacitidine Compared with Supportive Care.

Response Rates Using International Working Group (IWG) Criteria in Patients with Myelodysplastic Syndromes (MDS) Treated with Azacitidine.

A New Validated Myelodysplastic Syndrome (MDS) Prognostic Model for Use When Cytogenetics Are Unavailable.

Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011

Sequential Phase II Studies of Flavopiridol by 72-Hour Continuous Infusion and 1-Hour Intravenous Bolus for the Treatment of Relapsed B-Cell Chronic Lymphocytic Leukemia: Results from CALGB Study 19805.

Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only